Gold World

Special Report
July, 2008

The Single-Best Biotech Stock to own for the 21st Century



You can download the PDF version here: The Single-Best Biotech Stock to own for the 21st Century



Gold World

If you think you've missed the
boat on Gold...think again!

Gold continues to break multi-year highs, putting an exclamation mark on a metals bull market that has already made fortunes for some far-sighted investors...

Now it's your turn.

Sign Up for the FREE Gold World e-Letter.

Simply Enter Your E-mail Below:


Your Privacy is Assured.




Gold World, Copyright © 2008, Angel Publishing LLC. All rights reserved. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Gold World as well as a link to www.goldworld.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Gold World does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.